The Multidisciplinary Association for Psychedelic Research (MAPS) has announced a milestone in their push to legitimize MDMA as a clinical treatment for post-traumatic stress disorder (PTSD). MDMA-assisted psychotherapy has been granted an Expanded Access program by the Food and Drug Administration (FDA).
As part of the program, 50 patients who suffer from treatment-resistant PTSD will receive the treatment at up to 10 qualified sites. MAPS plans to submit data from the first 35 patients to the FDA in hopes of convincing the U.S. federal agency to expand the program further.
“We commend FDA for recognizing the great unmet medical need of PTSD by allowing access to MDMA-assisted psychotherapy on a compassionate basis for people with treatment-resistant PTSD,” wrote MAPS Founder and Executive Director Rick Doblin, Ph.D in a statement. “We are delighted to begin generating real-world evidence about this potential new treatment.”
MDMA was designated a Schedule I controlled substance in the U.S. in 1985, meaning that it was determined to have a high potential for abuse and no accepted medical use. MAPS was founded the following year. The organization advocates for research and education that benefits individuals who might benefit from treatments involving entheogens and other psychedelics. To date, they've raised over $70 million to that end.
Musical Story, Yes: STS9 Takes Colorado to "Sky World" At First Shows Back
After over a year without playing a live show, STS9 returned to the stage to deliver seven spectacular sets to their fans in Colorado over the weekend.
Thailand's Hospitals Are On the "Brink of Collapse" After COVID-19 Spreads Through Nightclubs
According to a report by The Independent, Thailand's third wave of the virus emanated from a spread in the country's nightlife in April.
This Artist Recorded Audio From His Own Firing—Then Remixed It Into a Banger
"I really feel like this remix is the epitome of life giving you lemons and you turning it into lemonade."
By 2021, MAPS expects to make MDMA available by prescription for sufferers of treatment-resistant PTSD.